Mostrar el registro sencillo

dc.contributor.authorFortea Ormaechea, José Ignacio
dc.contributor.authorPuente, Ángela
dc.contributor.authorCuadrado Lavín, Antonio 
dc.contributor.authorHuelin, Patricia
dc.contributor.authorPellón, Raúl
dc.contributor.authorGonzález Sánchez, Francisco José
dc.contributor.authorMayorga, Marta
dc.contributor.authorCagigal, María Luisa
dc.contributor.authorGarcía Carrera, Inés
dc.contributor.authorCobreros, Marina
dc.contributor.authorCrespo, Javier
dc.contributor.authorFábrega García, Emilio 
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.date.accessioned2025-12-01T13:04:25Z
dc.date.available2025-12-01T13:04:25Z
dc.date.issued2020
dc.identifier.issn1661-6596
dc.identifier.issn1422-0067
dc.identifier.urihttps://hdl.handle.net/10902/38335
dc.description.abstractLiver disease resulting from heart failure (HF) has generally been referred as "cardiac hepatopathy". One of its main forms is congestive hepatopathy (CH), which results from passive venous congestion in the setting of chronic right-sided HF. The current spectrum of CH differs from earlier reports with HF, due to ischemic cardiomyopathy and congenital heart disease having surpassed rheumatic valvular disease. The chronic passive congestion leads to sinusoidal hypertension, centrilobular fibrosis, and ultimately, cirrhosis ("cardiac cirrhosis") and hepatocellular carcinoma after several decades of ongoing injury. Contrary to primary liver diseases, in CH, inflammation seems to play no role in the progression of liver fibrosis, bridging fibrosis occurs between central veins to produce a "reversed lobulation" pattern and the performance of non-invasive diagnostic tests of liver fibrosis is poor. Although the clinical picture and prognosis is usually dominated by the underlying heart condition, the improved long-term survival of cardiac patients due to advances in medical and surgical treatments are responsible for the increased number of liver complications in this setting. Eventually, liver disease could become as clinically relevant as cardiac disease and further complicate its management.es_ES
dc.description.sponsorshipJosé Ignacio Fortea Ormaechea was supported by the Health Research Institute Marqueés de Valdecilla. IDIVAL. Santander. NEXT VAL17/07 grantes_ES
dc.format.extent23 p.es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rights© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.es_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.sourceInternational Journal of Molecular Sciences, 2020, 21(24), 9420es_ES
dc.subject.otherCirrhosises_ES
dc.subject.otherPortal hypertensiones_ES
dc.subject.otherHeart failurees_ES
dc.subject.otherHeart transplantationes_ES
dc.titleCongestive hepatopathyes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherVersionhttps://doi.org/10.3390/ijms21249420es_ES
dc.rights.accessRightsopenAccesses_ES
dc.identifier.DOI10.3390/ijms21249420
dc.type.versionpublishedVersiones_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.Excepto si se señala otra cosa, la licencia del ítem se describe como © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.